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Abstract
Background In children, estimated glomerular filtration rate
(eGFR) methods are hampered by inaccuracy, hence there is
an obvious need for safe, simplified, and accurate measured
GFR (mGFR) methods. The aim of this study was to evaluate
different formulas and determine the optimal sampling points
for calculating mGFR based on iohexol clearance measure-
ments on blood samples drawn at two time points (GFR2p).
Methods The GFR of 96 children with different stages of
chronic kidney disease (CKD) (median age 9.2 years, range
3 months to 17.5 years) was determined using the iohexol
plasma clearance, with blood sampling at seven time points
within 5 h (GFR7p) as the reference method. Median GFR7p
was 65.9 (range 6.3–153) mL/min/1.73 m2. The performance
of seven different formulas with early and late normalization
to body surface area (BSA) was validated against the
reference.
Results The highest percentage (95.8 %) of GFR2p within 10
% of the reference was calculated using the formula of Jødal
and Brøchner–Mortensen (JBM) from 2009, with sampling at
2 and 5 h. Normalization to BSA before correction of the
distribution phase improved the performance of the original
Brøchner–Mortensen method from 1972; P10 of 92.7 % com-
pared to P10 of 82.3 % with late normalization, and a similar
result was obtained with other formulas.
Conclusions GFR2p performed well across a wide spectrum
of GFR levels with the JBM formula. Several other formulas
tested performed well provided that early BSA normalization
was performed. Blood sampling at 2 and 5 h is recommended
for an optimal GFR2p assessment.
Keywords Glomerular filtration rate . Child . Chronic kidney
disease . Renal function .Method
Introduction
Measurement of glomerular filtration rate (GFR) by
iohexol plasma clearance was introduced in the 1980s [1]
and has increasingly been applied due to safety and good
performance [2–6]. Plasma clearance, in comparison to re-
nal clearance, eliminates the errors linked to inaccurate
urine collection [1, 5, 7–10] and can be calculated as the
ratio between the amount of the injected substance and the
area under the plasma concentration curve. The slope–in-
tercept technique (i.e., one-pool technique) needing a min-
imum of two blood samples, has been broadly used as it
eliminates the need for many blood samples and extensive
clinical examination. Chantler et al.’s fixed constant meth-
od [Clearance (Cl) = 0.80 × Cl1 (mL/min/1.73 m
2)] [11]
has been shown to be inaccurate [12, 13], leading to the
development of a second-order polynomial of the form
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aCl1 + bCl1
2, by Brøchner–Mortensen in 1972 (BMadult)
which has been widely used in its original form as well as
in different subsequent modifications [14–17]. Single-
point methods have also been developed, but these have
generally been shown to perform more poorly than the
slope–intercept technique [18–20]. Importantly, in the
original Brøchner–Mortensen formula, normalization to
1.73 m2 body surface area (BSA) was undertaken after
correction for the distribution phase, i.e., after the comple-
tion of the entire GFR calculation. When the formula was
modified for children, normalization to BSA was done be-
fore correction for the distribution phase (BMchild) [15].
Of note, the British Nuclear Medicine Guidelines recom-
mend early BSA normalization both in children and adults
and also suggested using average coefficient values of
BMadult and BMchild (BMcombined) [17]. Despite these
recommendations, some pediatric nephrology centers have
published several studies using the original BMadult with-
out early normalization in children [21, 22]. In 2007,
Fleming developed a new formula that includes early
BSA normalization and a constant factor (Flem) [12].
Jødal and Brøchner–Mortensen further refined this new
formula (JBM), where the constant factor was replaced
by a BSA-dependent factor [13, 23]. Schwartz and co-
workers have proposed several new formulas; a modifica-
tion of the BMchild formula (SAM), and a minor change of
the JBM formula by introducing a constant factor (NSM)
[5, 6, 24]. The studies of Brøchner–Mortensen’s group
were performed with 51Cr-EDTA, the group of Fleming
used 99mTc-DTPA, and the Schwartz group used iohexol.
GFR measurements with all these three substances are
comparable those of inulin clearance. However, iohexol
is the only method without ionizing radiation, making it
the preferred substance in many centers, especially for pe-
diatric patients [10].
A major and as yet unsettled issue is the optimal sampling
time points for the slope–intercept technique; to date, no con-
sensus has been reached regarding a recommendation for a
GFR measurements method in children that is both feasible
and less time-consuming. Some centers have chosen shorter
procedures with the latter blood sampling as early as 3 h after
the injection of iohexol [21, 25]. However, current knowledge
on optimal time points is limited [9] and needs further
investigation.
The purposes of our study were to: (1) assess the accu-
racy of the different formulas for measuring GFR (mGFR)
in blood samples drawn at two time points (GFR2p) by
comparison with reference iohexol plasma clearance mea-
surements, (2) find the optimal time points for blood sam-
pling within a feasible timeframe (i.e., last blood sampling
5 h after injection), and (3) examine the effect on GFR
determination of early and late BSA correction, i.e., the
before and after- versions (Table 1).
Patients and methods
Patients
A total of 96 children with chronic kidney disease (CKD)
were recruited for this study (ClinicalTrials.gov Identifier
NCT01092260), of whom 54 were treated at Haukeland
University Hospital, Bergen, Norway and 42 were treated at
Oslo University Hospital, Oslo, Norway. The median age of
the children (55 males, 41 females) was 9.2 years (range
3 months to 17.5 years), the median weight was 28.2 (range
6.6–84.6) kg, and the median height was 133.9 (range 59–
177) cm.Median reference GFR based on seven blood sample
time points (GFR7p) was 65.9 (range 6.3–153) mL/min/
1.73 m2. The patients were distributed evenly over the differ-
ent GFR stages, with 28, 27, 23, and 18 patients in CKD stage
1, 2, 3, and 4–5, respectively. None of the children enrolled in
the study had edema.
Methods
Iohexol was administered as Omnipaque® 300 mg I/mL
(GE Healthcare, Oslo, Norway; i.e., 647 mg iohexol/mL)
given in a dose adapted to body weight as follows: <10 kg,
1 mL; 10–20 kg, 2 mL; 20–30 kg, 3 mL; 30–40 kg, 4 mL;
≥40 kg, 5 mL Omnipaque®. The syringe with iohexol was
weighed before and after the injection to an accuracy of
0.01 g. The dose of iohexol (in milligrams) was calculated
by first multiplying the difference in syringe weight by the
concentration of iohexol (647 mg/mL) and then dividing
the product by the density of iohexol at room temperature
(1.345 g/mL). The iohexol bolus was followed by an injec-
tion of 15 mL physiologic saline.
Blood samples (0.5 mL) were drawn from a different intra-
venous access at 10, 30, 120, 180, 210, 240, and 300 min after
the injection of iohexol. In 29 of the 96 patients, the second
blood sample was drawn after 60 min instead of 30 min.
Blood was also obtained before the infusion of iohexol to
exclude interference of other metabolites with the iohexol as-
say. The blood was allowed to stand for 30–60 min before
being centrifuged at 1000–1300 g for 10 min. Serum was
stored at −20 °C until analysis at one center (Haukeland
University Hospital); the samples collected at the other center
were sent frozen on dry ice for iohexol analysis.
Serum concentrations of iohexol were determined by high
performance liquid chromatography. The concentration of
iohexol was calculated from the area under the largest iohexol
peak as compared to an internal calibration curve prepared for
each set of samples. Calibrators were made up from an iohexol
stock solution, 180 mg I/mL (i.e., 388 mg iohexol/mL,
Omnipaque®, GE Healthcare), which were diluted in pooled
normal plasma to 100, 50, and 10 μg/mL, respectively. Small
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aliquots of the calibrators were stored frozen at −20 °C in vials
for up to 1 year. The accuracy of the method was assessed by
an external quality assurance program (Equalis, Uppsala,
Sweden), and the precision, calculated as the total coefficient
of variation over several months, was 4.1 % at 10 mg/L, 3.8 %
at 25–290 mg/L, and 3.3 % at >290 mg/L. The iohexol anal-
ysis is accredited by the Norwegian Accreditation and com-
plies with the requirements of NS-EN ISO I5189.
Calculations and statistics
The 7-point GFR (GFR7p) was calculated according to
Sapirstein, as described by Schwartz et al. [5, 26] (Table 1).
GFR was normalized to 1.73 m2 BSA by the ratio 1.73/BSA,
using the formula of Haycock et al. [27]. The 2-point GFR
(GFR2p) was calculated with the slope–intercept technique
and corrected for the distribution phase as described by
Table 1 Methodology of
glomerular filtration rate
calculations
Calculations and methodsa Formulab
Calculation of reference GFR (GFR7p)
Absolute GFR7p (mL/min) [5] GFR =Cl = I/(expA/α + expB/β)
BSA normalized GFR7p (mL/min/1.73 m2) ClBSA = Cl × 1.73/BSA
Calculations of 2-point GFR (GFR2p)
Cl1 Cl1 = I/ expA/α
BSA normalized Cl1 Cl1,BSA = Cl1 × 1.73/BSA
BMadultafter (original)
c [14] Cl = 0.9908 × Cl1 – 0.001218 × Cl1
2
ClBSA = Cl × 1.73/BSA
BMadultbefore (adapted) ClBSA = 0.9908 × Cl1,BSA − 0.001218 × Cl1,BSA2
BMchildbefore (original)
d [15] ClBSA = 1.01 × Cl1, BSA − 0.0017 × Cl1, BSA2
BMchildafter (adapted) Cl = 1.01 × Cl1 – 0.0017 × Cl1
2
ClBSA = Cl × 1.73/BSA
BMcombbefore (original)
e [17] ClBSA = 1.0004 × Cl1,BSA – 0.00146 × Cl1, BSA
2
BMcombafter (adapted) Cl = 1.0004 × Cl1 − 0.00146 × Cl12
ClBSA = Cl × 1.73/BSA
Flembefore (original)
e [12] ClBSA = Cl1,BSA /[1 + 0.0017 × Cl1,BSA]
Flemafter (adapted) Cl = Cl1 /[1 + 0.0017 × Cl1]
ClBSA = Cl × 1.73/BSA
JBMbefore (original)




e [23] Cl = Cl1 /1 + f × Cl1
f = 0.0032BSA−1.3
ClBSA = Cl × 1.73/BSA
SAMbefore (original)
d [6] ClBSA = 1.0019 × Cl1,BSA − 0.001258 × Cl1, BSA2
SAMafter (adapted) Cl = 1.0019 × Cl1 − 0.001258 × Cl12
ClBSA = Cl × 1.73/BSA
NSMbefore (original)
e [24] ClBSA = Cl1,BSA /[1 + 0.0012 × Cl1,BSA/100]
NSMafter (adapted) Cl = Cl1 /[1 + 0.0012 × Cl1/100]
ClBSA = Cl × 1.73/BSA
aGFR7p, Reference method for measured glomerular filtation rate (mGFR) using the iohexol plasma clearance
formula, with blood sampling at 7 time points within 5 h; GRF2p, mGFR based on iohexol clearance measure-
ments on blood samples drawn at 2 time points; BSA , body surface area in m2 where BSA = 0.024265 ×W0.5378
× H0.3964 (with W the body weight in kg and H the height in cm); Cl1, clearance of iohexol based solely on the
slow phase of the elimination curve, using the slope–intercept technique, but without correction for the distribu-
tion phase; before, early BSA normalization; after, late BSA normalization. For further explanation, see the refer-
ences cited next to the formula and refer to the Introduction
b I is the dose of iohexol in milligrams, expA is the intercept of the slow curve (elimination phase, log concen-
tration vs. time), with α its corresponding slope; expB, the intercept of the fast curve (distribution phase), with β
its corresponding slope
c Formula developed in adults
d Formula developed in children
e Formula developed in children and adults
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Brøchner-Mortensen [14], and was normalized to 1.73 m2
BSA [27]. Due to the great variability of body size in the
pediatric population and differences between children and
adults, we tested the impact of BSA normalization before or
after the mathematical correction for the distribution phase
[i.e., normalization interposed in the calculation (early) or un-
dertaken after the entire GFR calculation is completed (late)].
Table 1 shows the formulas used in the evaluation.
The performances of the different formulas for GFR2p
were compared. Accuracy was calculated as the percentage
of patients with values within ±5, 10, and 15 % (P5, P10 and
P15, respectively) of the reference method (GFR7p).
Estimates of bias as a measure of trueness, as well as assess-
ment of limits of agreement and correlation as measures of
dispersion, were systematically performed. As a general mea-
sure of accuracy, the 95 percentile of deviations from the ref-
erence method (95POD), was also determined, with 90 %
confidence intervals (CI) calculated by bootstrapping to pro-
vide estimates of variability [28] (Tables 2–4).
McNemar’s test for paired categorical variables was used
to compare P10 values. For the evaluation of optimal blood
sampling times, pairs of 2 and 3, 2 and 4, 2 and 5, and 3 and
5 h were chosen. As the time points 2 and 5 h were considered
to be the best sampling times (Table 2), these were chosen for
the comparison of the different methods (Table 3).
Subanalyses were performed for age groups (<6, <10, and ≥10
years), BSA groups (<0.5, <1.0, and <1.45 m2), and stage of
CKD (<30, 30 to <60, 60 to <90, and ≥90 mL/min/1.73 m2)
(Table 4). The software packages Excel, Analyse-it V2.26
(both Microsoft Corp., Redmond, WA), and SPSS Statistics
version 22 (IBMCorp., Armonk, NY) were used for statistical
analysis.
Results
Table 2 shows the evaluation of optimal time and interval for
GFR2p blood sampling using the formulas JBM,
BMadultbefore, and Flembefore. The best results were obtained
when blood samples were drawn at 2 and 5 h with JBM; the
P10 at these time points was 95.8 % compared to <90 % with
the three alternative sampling time points pairs (p < 0.05)).
The 95POD value was lowest (9.8) when the GFR2p was
calculated with JBM using blood drawn at 2 and 5 h (Table 2).
The performance of the seven different formulas, used as
presented in their original publication, is shown in Table 3.
The performance of BMadultbefore is also presented since this
formula has been broadly recommended (Fleming et al. 2004).
Figure 1 shows the accuracy of the various formulas and their
before and after normalizations to BSA, as defined in Table 1.
All before formulas demonstrated high correlation factors
(r ≥ 0.99), and relatively small mean biases of −2.02 to
2.15 mL/min/1.73 m2. Three formulas showed a high perfor-
mance: the modified version of the classical BMadult
(BMadultbefore), Flembefore, and JBM. BMbefore showed the
smallest mean bias and the best 95 % limits of agreement as
well as the highest P5, whereas JBM had the highest P10 score
(Table 3). When the different formulas were evaluated by the
Table 2 Effect of different blood sampling times and intervals
Formulaa Sampling
schemes (h)
Mean bias (95 % CI)
(mL/min/1.73 m2)
95 % Limits of agreement
(mL/min/1.73 m2)
R P5 (%)b P10 (%)b P15 (%)b 95 Percentile of deviations
(90 % CI) (%)c
BMadultbefore 2 and 3 −0.05 (−1.10 to 1.00) −10.2 to 10.1 0.9877 60.4 79.2 89.6 26.4 (16.5–64.9)
BMadultbefore 2 and 4 0.30 (−0.60 to 1.19) −8.4 to 8.9 0.9911 67.7 87.5 95.8 14.12 (11.7–18.5)
BMadultbefore 2 and 5 −0.20 (−0.70 to 1.09) −8.5 to 8.9 0.9910 78.1 92.7 97.9 12.4 (8.9–17.0)
BMadultbefore 3 and 5 1.07 (−0.16 to 2.31) −10.9 to 13.0 0.9840 56.3 86.5 95.8 15.2 (11.7–18.7)
Flembefore 2 and 3 −0.94 (−1.99 to 0.11) −11.1 to 9.2 0.9877 59.4 82.3 89.6 25.8 (16.6–50.0)
Flembefore 2 and 4 −0.60 (−1.50 to 0.30) −9.3 to 8.1 0.9911 70.8 88.5 95.8 13.7 (10.8–22.8)
Flembefore 2 and 5 −0.69 (−1.59 to 0.21) −9.4 to 8.0 0.9911 77.1 92.7 97.9 10.6 (9.8–16.1)
Flembefore 3 and 5 0.19 (−1.04 to 1.41) −11.6 to12.0 0.9837 63.5 86.5 95.8 14.4 (11.7–17.0)
JBM 2 and 3 −1.82 (−2.87 to −0.76) −12.0 to 8.4 0.9879 56.3 82.3 89.6 25.5 (16.7–64.7)
JBM 2 and 4 −1.46 (−2.38 to −0.55) −10.3 to 7.4 0.9913 64.6 89.6 96.9 14.1 (11.0–20.4)
JBM 2 and 5 −1.69 (−2.57 to −0.82) −10.1 to 6.8 0.9919 74.0 95.8 99.0 9.8 (7.6–11.2)
JBM 3 and 5 −0.72 (−1.92 to 0.48) −12.3 to 10.9 0.9840 63.5 88.5 95.8 14.6 (11.7–17.1)
Evaluation of optimal time and interval for blood sampling was investigated using four different sampling schemes after iohexol injection: 2 and 3, 2 and
4, 2 and 5, and 3 and 5 h, respectively. N = 96.patients. By comparison with the reference method (GFR7p), mean bias, 95 % limits of agreement, and
correlation coefficient (R) were calculated
a The GFR (in mL/min/1.73 m2 ) was calculated by 2-point GFR using the formulas JBM, BMadultbefore, and Flembefore
b Accuracy was assessed as P5, P10, and P15, which is the percentage of patients within ±5, 10, and 15 % of the reference method, respectively
c The 95 percentile of deviations (95POD) [with 90 % confidence interval (CI)] shows the maximum deviation for 95 % of the results
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95POD, JBM showed the best value for accuracy. When BSA
normalization was performed after the correction for the dis-
tribution phase, only JBMafter performed identically to
JBMbefore due to a separate and equivalent mathematical for-
mula for this purpose in JBM. All of the other formulas per-
formed substantially better with early compared to late BSA
normalizations, i.e., before versions versus after versions
(Table 3; Fig. 1). In general, GFR2p calculated with the after
versions (GFR2pafter) gave an overestimation of 2.88–
5.03 mL/min/1.73 m2 (mean bias) compared to GFR7p, with
relatively broad limits of agreement. The correlation factor
was 0.979–0.985, and only 78.1–82.3 % of the results were
within ±10 % of the reference method. All GFR2pafter had P5
and P15 of <60 and <90 %, respectively.
Difference plots of BMadultafter and BMadultbefore are giv-
en in Fig. 2a, b; these demonstrate the importance of normal-
izing to 1.73 m2 before correction of the distribution phase in
the widely used BMadult (p = 0.002 by McNemar’s test for
P10) The difference plot of the formula that performs the best,
i.e., JBM, is shown in Fig. 2c.When the results were classified
according to different CKD stages, age, and BSA, the best
accuracy in general was achieved by the JBM formula
(Table 4).
Discussion
The results of our study show that the optimum time points for
two-point blood sampling in children are 2 and 5 h after
iohexol injection (Table 2). These time points are in accor-
dance with the following mathematical and analytical consid-
erations: a correct determination of the slope of the slow phase
of the iohexol elimination curve is of crucial importance in
GFR measurements based on the slope–intercept technique.
When only two data points are used for a GFR calculation, the
uncertainty in the assessment of this slope is dependent on
both the separation distance between these two points and
the analytical variation. With a short time-lapse between the
two samplings, the difference between the data points is small,
which implies that the analytical variation will contribute rel-
atively more to the uncertainty of the slope than when the data
points are well separated. A too close proximity in sampling
times therefore introduces an unnecessary inaccuracy in the
GFR determination, which was confirmed in our study by the
high 95POD values of >25 for GFR2p based on sampling at 2
and 3 h . If sampling is undertaken too early, the elimination of
iohexol has not yet reached the slow and linear phase, leading
to an incorrect (too high) slope. Therefore, sampling which is
too early is expected to result in an overestimation of the GFR,
as has been shown in several studies [21, 25]. This is especial-
ly relevant at the lower GFR levels [5, 6, 24]. For clinical use,
some centers will prefer to shorten the procedure and accept
the cost of a lower accuracy, sampling at 2 and 3 h or at 2 and
4 h instead of 2 and 5 h. Other centers will choose to wait for
5 h after injection before collecting blood samples as long as
this strategy results in a mGFR of higher quality.
Another important finding of our study is the dependency
of the formulas on the timing of BSA normalization (Fig. 1;
Table 3,), as recently discussed by Pottel et al. and Blake et al.
[29–31]. A significant difference and substantially lower per-
formance was found when BSA normalization was done after
the correction for the distribution phase; for example, the ac-
curacy of BMadultafter was clearly inferior to that of
BMadultbefore (p value of 0.002 for P10). The only exception
was the JBM since it provides two mathematically equivalent
formulas, one for normalization before and the other for
Table 3 Performance of different formulas
Formulaa Mean bias (95 % CI)
(mL/min/1.73 m2)
95 % limits of agreement
(mL/min/1.73 m2)
R P5 (%)b P10 (%)b P15 (%)b 95 Percentile of deviations
(90 % CI) (%)c
BMadultafter 3.70 (2.38 to 5.02) −9.1 to 16.5 0.9848 57.3 82.3 88.5 20.4 (16.3–24.5)
BMadultbefore 0.20 (−0.70 to 1.09) −8.5 to 8.9 0.9910 78.1 92.7 97.9 12.4 (8.9–17.0)
BMchildbefore −2.02 (−3.07 to −0.97) −12.2 to 8.2 0.9900 77.1 89.6 96.9 11.9 (10.9–16.2)
BMcombbefore −0.92 (−1.86 to 0.02) −10.0 to 8.2 0.9907 78.1 91.7 97.9 11.3 (9.2–16.5)
Flembefore −0.69 (−1.59 to 0.21) −9.4 to 8.0 0.9911 77.1 92.7 97.9 10.6 (9.8–16.1)
JBM −1.69 (−2.57 to −0.82) −10.1 to 6.8 0.9919 74.0 95.8 99.0 9.8 (7.6–11.2)
SAMbefore 0.75 (−0.16 to 1.65) −8.0 to 9.5 0.9910 77.1 92.7 97.9 13.2 (9.7–16.3)
NSMbefore 2.15 (1.17 to 3.12) −7.3 to 11.6 0.9910 72.9 88.5 94.8 15.4 (12.5–16.8)
Glomerular filtration rate (GFR) (mL/min/1.73m2) was calculated by the 2-point GFR using the different formulas as indicated and with blood sampling
at 2 and 5 h after injection.N = 96.patients.Mean bias (95% confidence interval), 95% limits of agreement, and correlation coefficient (R) were calculated
by comparison with the reference method (GFR7p)
a The GFR (in mL/min/1.73 m2 ) was calculated by 2-point GFR using the formulas: JBM, BMadultbefore, and Flembefore
b Accuracy, assessed as P5, P10, and P15, which is the percentage of patients within ±5, 10, and 15 % of the reference method, respectively
c The 95POD (with 90 % CI) shows the maximum deviation for 95 % of the results
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Table 4 Subgroup analysis with glomerular filtration rate calculated using the formulas BMadultbefore,, BMchild, Flembefore, and JBM
Patient groups N Method Mean bias (95 % CI)
(mL/min/1.73 m2)











(90 % CI) (%)b
All participants 96 BMadultbefore 0.20 (−0.70 to 1.09) −8.5 to 8.9 0.9910 78.1 92.7 97.9 12.4 (8.9–17.0)
BMchildbefore −2.02 (−3.07 to −0.97) −12.2 to 8.2 0.9900 77.1 89.6 96.9 11.9 (10.9–16.2)
Flembefore −0.69 (−1.59 to 0.21) −9.4 to 8.0 0.9911 77.1 92.7 97.9 10.6 (9.8–16.1)
JBM −1.69 (−2.57 to −0.82) −10.1 to 6.8 0.9919 74.0 95.8 99.0 9.8 (7.6–11.2)
Age <6 years 33 BMadultbefore 1.13 (−0.34 to 2.61) −7.0 to 9.3 0.9909 69.7 87.9 100 12.8 (9.7–13.4)
BMchildbefore −0.94 (−2.38 to 0.51) −8.9 to 7.1 0.9914 75.8 90.9 100 11.1 (9.8–11.6)
Flembefore −1.01 (−2.93 to 0.93) −11.7 to 9.7 0.9870 69.7 87.9 97.0 13.1 (10.0–18.4)
JBM −2.00 (−3.62 to −0.39) −10.9 to 6.9 0.9888 51.5 93.9 100 11.7 (8.0–14.0)
Age <10 years 52 BMadultbefore 0.88 (−0.48 to 2.23) −8.7 to 10.4 0.9973 71.2 88.5 96.2 14.6 (11.3–17.9)
BMchildbefore −1.22 (−2.59 to 0.14) −10.8 to 8.4 0.9879 76.9 90.4 96.2 12.9 (10.1–20.2)
Flembefore −0.72 (−2.10 to 0.66) −10.4 to 9.0 0.9892 71.2 90.4 96.2 12.7 (9.8–18.4)
JBM −1.99 (−3.35 to −0.63) −11.6 to 7.6 0.9873 61.5 94.2 98.1 11.9 (7.8–19.2)
Age ≥10 years 44 BMadultbefore −0.61 (−1.75 to 0.53) −8.0 to 6.7 0.9948 86.4 97.7 100 8.8 (7.1–12.3)
BMchildbefore −2.96 (−4.62 to -1.31) −13.6 to 7.7 0.9930 77.3 88.6 97.7 12.2 (10.1–16.2)
Flembefore −0.67 (−1.82 to 0.49) −8.1 to 6.8 0.9934 84.1 95.5 100 10.2 (7.3–11.6)
JBM −1.34 (−2.4 to −0.26) −8.3 to 5.6 0.9957 88.6 97.7 100 9.63 (5.8–10.7)
BSA <0.5 m2 11 BMadultbefore 0.32 (−2.23 to 2.87) −7.1 to 7.8 0.9938 63.6 90.9 100 NA
BMchildbefore 0.98 (−2.49 to 4.45) −9.1 to 11.1 0.9911 72.7 81.8 100 NA
Flembefore −0.35 (−3.01 to 2.32) −8.1 to 7.4 0.9939 72.7 90.9 100 NA
JBM −2.67 (−6.42 to 1.07) −13.6 to 8.2 0.9921 45.5 90.9 100 NA
BSA <1.0 m2 47 BMadultbefore 1.31 (0.09–2.53) −6.8 to 9.4 0.9915 72.3 89.4 97.9 13.0 (10.54–17.9)
BMchildbefore −0.66 (−1.82 to 0.50) −8.4 to 7.1 0.9919 78.7 91.5 97.9 11.3 (9.6–15.2)
Flembefore 0.42 (−0.77 to 1.60) −7.5 to 8.3 0.9914 74.5 91.5 97.9 11.3 (9.2–16.1)
JBM −1.69 (−2.90 to −0.48) −9.7 to 6.4 0.9910 61.7 95.7 100 9.9 (7.6–14.0)
BSA <1.45 m2 77 BMadultbefore 0.59 (−0.44 to 1.62) −8.3 to 9.5 0.9894 75.3 90.9 97.4 12.7 (9.3–17.01)
BMchildbefore −1.44 (−2.51 to −0.37) −10.7 to 7.8 0.9895 77.9 90.9 97.4 11.7 (9.8 – 15.7)
Flembefore −0.29 (−1.31 to 0.73) −9.1 to 8.6 0.9893 76.6 92.2 97.4 11.0 (9.7–16.4)
JBM −1.70 (−2.73 to −0.68) −10.6 to7.2 0.9895 70.1 94.8 98.7 10.7 (7.8–14.5)
GFR 30 mL/min/1.73 m2 18 BMadultbefore −0.28 (−0.60 to 0.04) −1.5 to 1.0 0.9960 94.4 100 100 NA
BMchildbefore −0.11 (−0.43–0.20) −1.4 to 1.1 0.9960 94.4 100 100 NA
Flembefore −3.00 (−0.63 to 0.03) −1.6 to 0.99 0.9960 94.4 100 100 NA
JBM −0.36 (−0.69 to −0.03) −1.7 to 1.0 0.9959 88.9 100 100 NA
GFR 30–59 mL/min/1.73 m2 23 BMadultbefore 0.21 (−0.40 to 0.83) −2.6 to 3.0 0.9836 91.3 95.7 100 10.2 (4.7–11.3)
BMchildbefore 0.01 (−0.60 to 0.62) −2.8 to 2.8 0.9835 91.3 95.7 100 9.9 (4.6–10.9)
Flembefore −0.15 (−0.76 to 0.46) −2.9 to 2.6 0.9835 91.3 95.7 100 9.4 (4.5–10.4)
JBM −0.65 (−1.30 to 0.01) −3.6 to 2.3 0.9817 87.0 100 100 7.6 (5.6–8.0)
GFR 60 to <90 mL/min/1.73 m2 27 BMadultbefore 0.90 (−0.62 to 2.43) −6.6 to 8.4 0.9284 77.8 88.9 96.3 16.1 (9.9–17.9)
BMchildbefore −1.18 (−2.75 to 0.39) −9.0 to 6.6 0.9284 74.1 92.6 96.3 13.5 (9.0–15.2)
Flembefore −0.28 (−1.81 to 1.25) −7.9 to 7.3 0.9284 77.8 88.9 96.3 14.3 (9.3–16.1)
JBM −1.83 (−3.11 to −0.55) −8.2 to 4.5 0.9498 66.7 96.3 100 9.4 (7.1–10–7)
GFR ≥ 90 mL/min/1.73 m2 28 BMadultbefore −0.20 (−3.00 to 2.61) −14.4 to 14.0 0.8890 57.1 89.3 96.4 14.9 (10.3–17.0)
BMchildbefore −5.73 (−8.66 to −2.79) −20.6 to 9.1 0.8824 57.1 75.0 92.9 18.4 (11.8–20.2)
Flembefore −1.78 (−4.56 to 0.99) −15.8 to 12.2 0.8914 53.6 89.3 96.4 14.8 (9.8–18.4)
JBM −3.28 (−5.98 to 0.57) −16.9 to 10.4 0.8995 60.7 89.3 96.4 16.9 (9.7–19.2)
Glomerular filtration rate (GFR) (mL/min/1.73 m2 ) was calculated bythe 2-point GFR using the formulas: BMadultbefore, BMchild, Flembefore, and JBM.
Blood was sampled at 2 and 5 h after injection, and the results were subdivided according to age, BSA, and chronic kidney disease (CKD) stages as
indicated. Mean bias (95 % CI), 95 % limits of agreement, and correlation coefficient (R) were calculated by comparison with the reference method
(GFR7p)
NA, Not applicable due to insufficient data
a Accuracy was assessed as P5, P10, and P15, which is the percentage of patients within ± 5, 10 and 15 % of the reference method, respectively
b The 95POD (with 90 % CI) shows the maximum deviation for 95 % of the results
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normalization after, giving identical results [23]. The publica-
tion in 1972 by Brøchner–Mortensen of the correction for the
distribution phase of the one-pool slope–intercept technique
using a second-order polynomial [14] was a break-through in
terms of simplicity and accuracy for GFRmeasurements. This
method has been broadly used in its original form as well as in
different modifications in both children and adults [9, 17, 20].
As early as in 1974 Brøchner–Mortensen et al. showed the
importance of the different body sizes in children, and the
pediatric formula was only meant to be used with early
(before) normalization [15]. The study was based on a rela-
tively small cohort of 30 children which may explain why
some pediatric nephrologists have chosen to use the original
method developed for adult patients (BMadultafter), which was
based on a considerably higher number of patients. It is of
great importance that researchers are aware that the relatively
low performance of the slope–intercept technique in some
pediatric studies using BMadultafter is largely due to the use
of BSA normalization after the entire GFR calculation was
completed instead of being interposed in the calculation
[21, 22]. In our view, this fact has not always been properly
acknowledged and may be a source of erroneous conclusions
in some previous studies.
All before formulas performed relatively well, with a P10
ranging from 88.5 to 95.8 % (Table 3). The JBM formula
showed the best values for accuracy in this cohort, based on
the highest P10 (95.8 %) and the lowest 95POD (9.8 %, 90 %
CI 7.6–11.2). Based on the 95POD values with confidence
intervals, the JBM formula performed significantly better than
the recently published NSMbefore formula (15.4 %, 90 % CI
12.5–16.8) (Table 3). The NSMbefore formula [24] was meant
to be an improvement of JBM. These two formulas are rela-
tively similar, but the innovative BSA-dependent correction
factor for the distribution phase in the JBM formula has been
replaced by a constant in the NSM formula, which probably
explains the latter’s lower performance. The BSA dependency
of the correction factor was recently confirmed in a study of
142 children and adults using 99mTc-DTPA–GFR [32]. JBM
was also significantly better than the BMadultafter (Table 3), as
well as the other after formulas (not shown). The other before
formulas shown in Table 3 were not statistically different due
to partly overlapping confidence intervals, but all showed
higher 95POD values than JBM.
In the subgroup analysis according to age, BSA, and
GFR (Table 4), the JBM formula showed the best accuracy
in all groups except for age of <6 years and GFR of
≥90 mL/min/1.73 m2. For the age group of <6 years, the
BMchildbefore formula had the highest P5 and lowest
95POD, but the JBM formula showed the highest P10.
Our findings suggest that these two formulas perform at a
similar level. In the smaller children with a BSA of <1 m2,
JBM had the best results, with the highest P10 and a lower
Fig. 1 Accuracy of 7 different formulas for calculating measured GFR
(mGFR) based on iohexol clearance measurements (see Table 1 for the
formulas and the Introduction for more details). GFR (mL/min/1.73 m2)
was calculated by 2-point GFR (GFR2p) using the different formulas as
indicated and with blood sampling at 2 and 5 h after injection. N = 96
patients. Color coding of graph: Black Fraction of results within 5 %
deviation of the reference method (GFR7p: GFR measured by the
iohexol clearance method with blood sampling at 7 time points within
5 h), gray additional fraction within 10 % deviation of reference method,
white additional fraction within 15 % deviation of reference method. Left
column of each column pair Body surface area (BSA) normalization to
1.73 m2 performed Bbefore^ the mathematical correction for the
distribution phase, right column of each column pair normalization
performed Bafter^ the entire GFR calculation was completed
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95POD compared to BMchildbefore, BMadultbefore, and
Flembefore, likely due to the BSA-dependent correction fac-
tor used in the JBM formula and not in any of the other
formulas validated in this study.
A limitation of our study is the lack of the true gold stan-
dard marker inulin. However, inulin clearance is cumbersome
and difficult to perform in children due to continuous intrave-
nous infusion and timed urine collections, the latter also with a
high risk of error, especially in children with urologic disorder,
which is a common cause of CKD in the pediatric population
[9]. Multipoint plasma clearance for GFR measurement is
seen as a high-quality procedure and the Btrue^ GFR with
the last time point within a normal working day [10, 17, 33].
The last time point of iohexol measurement at 5 h may limit
the value of the study in patients with a very low GFR, as true
GFR may differ from the reference GFR. The number of pa-
tients in our study was limited to 96 children, and the sub-
group analysis was therefore hampered by this low number of
patients. However, the validity of our study is strengthened by
comparisons of a high number of blood samples at different
time points.
Conclusion
The determination of GFR based on two-point iohexol plasma
clearance performed well in children at all ages across a wide
spectrum of GFR levels. The formula of Jødal and Brøchner–
Mortensen from 2009 showed the highest percentage of
GFR2p within 10 % of the reference GFR. Based on our
findings, the optimum time points for blood sampling in chil-
dren are 2 and 5 h after iohexol injection. The correct use of










































































Fig. 2 Bland–Altman plots between the glomerular filtration rate (GFR)
(mL/min/1.73 m2) calculated according to reference method (GFR7p)
and GFR calculated according to the BMadultafter formula (a), the
BMadultbefore formula (b), and the JBM formula (c). a GFR was
calculated by GFR2p according to the 1972 formula of Brøchner–
Mortensen (BMadultafter) with sampling at 2 and 5 h after injection.
BSA normalization to 1.73 m2 was performed after the entire GFR
calculation was completed. N = 96 patients. Y-axis Difference between
BMadultafter and the reference method (GFR7p), X-axis mean of the
two methods. Dotted lines ±10 % difference. b GFR was calculated by
GFR2p according to the 1972 formula of Brøchner–Mortensen
(BMadultbefore) with sampling at 2 and 5 h after injection. BSA
normalization to 1.73 m2 was performed before the mathematical
correction for the distribution phase. N = 96 patients. Y-axis Difference
between BMadultbefore and the reference method (GFR7p), X-axis mean
of the two methods.Dotted lines ±10 % difference. cGFRwas calculated
by GFR2p according to the 2009 formula of Jødal and Brøchner–
Mortensen (JBM) with sampling at 2 and 5 h after injection. N = 96
patients. Y-axis Difference between JBM and the reference method
(GFR7p), X-axismean of the twomethods.Dotted lines ±10% difference
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